Generic Oxtellar XR Availability
Last updated on Jun 11, 2025.
Oxtellar XR is a brand name of oxcarbazepine, approved by the FDA in the following formulation(s):
OXTELLAR XR (oxcarbazepine - tablet, extended release;oral)
-
Manufacturer: SUPERNUS PHARMS
Approval date: October 19, 2012
Strength(s): 150MG [RLD] [AB], 300MG [RLD] [AB], 600MG [RLD] [AB]
Is there a generic version of Oxtellar XR available?
A generic version of Oxtellar XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Oxtellar XR and have been approved by the FDA:
oxcarbazepine tablet, extended release;oral
-
Manufacturer: AJANTA PHARMA LTD
Approval date: February 22, 2024
Strength(s): 150MG [AB], 300MG [AB], 600MG [AB] -
Manufacturer: APOTEX
Approval date: July 13, 2023
Strength(s): 150MG [AB], 300MG [AB], 600MG [AB] -
Manufacturer: RICONPHARMA LLC
Approval date: November 22, 2024
Strength(s): 150MG [AB], 300MG [AB], 600MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxtellar XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 10,220,042
Issued: March 5, 2019
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 11,166,960
Issued: November 9, 2021
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 11,896,599
Issued: February 13, 2024
Inventor(s): Bhatt; Padmanabh P. et al.
Assignee(s): Supernus Pharmaceuticals, Inc. (Rockville, MD)Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified-release preparations containing oxcarbazepine and derivatives thereof
Patent 7,722,898
Issued: May 25, 2010
Inventor(s): Bhatt; Padmanabh P. et al.
Assignee(s): Supernus Pharmaceuticals, Inc. (Rockville, MD)Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Method of treating seizures using modified release formulations of oxcarbazepine
Patent 7,910,131
Issued: March 22, 2011
Inventor(s): Bhatt; Padmanabh P. et al.
Assignee(s): Supernus Pharmaceuticals, Inc. (Rockville, MD)Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 8,617,600
Issued: December 31, 2013
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 8,821,930
Issued: September 2, 2014
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 9,119,791
Issued: September 1, 2015
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 9,351,975
Issued: May 31, 2016
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 9,370,525
Issued: June 21, 2016
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
-
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent 9,855,278
Issued: January 2, 2018
Inventor(s): Bhatt Padmanabh P. & Kidane Argaw & Edwards Kevin
Assignee(s): Supernus Pharmaceuticals, Inc.Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Patent expiration dates:
- April 13, 2027✓
- April 13, 2027
More about Oxtellar XR (oxcarbazepine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: dibenzazepine anticonvulsants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Lamictal
Lamictal is an anti-epileptic medication used treat seizures in adults and children over 2 years ...
Carbamazepine
Carbamazepine is used to treat epileptic seizures and nerve pain such as trigeminal neuralgia ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Levetiracetam
Levetiracetam is used for bipolar disorder, epilepsy, hyperekplexia, neuralgia, new daily ...
Lyrica
Lyrica is used to control seizures, treat nerve pain and fibromyalgia. Learn about side effects ...
Topiramate
Learn about topiramate, an anticonvulsant used for seizures, migraine prevention, and weight loss ...
Diazepam
Diazepam is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. Learn ...
Lorazepam
Lorazepam is in a group of drugs called benzodiazepines and is used to treat anxiety disorders ...
Pregabalin
Pregabalin may be used to treat certain types of pain and used in combination with other ...
Lamotrigine
Lamotrigine is used for anxiety, bipolar disorder, borderline personality disorder, cyclothymic ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
